Axial Concentration Profiles and NO Flue Gas in a Pilot-Scale Bubbling Fluidized Bed Coal Combustor

Atmospheric bubbling fluidized bed coal combustion of a bituminous coal and anthracite with particle diameters in the range 500-4000 ím was investigated in a pilot-plant facility. The experiments were conducted at steady-state conditions using three excess air levels (10, 25, and 50%) and bed temperatures in the 750-900 °C range. Combustion air was staged, with primary air accounting for 100, 80, and 60% of total combustion air. For both types of coal, high NO concentrations were found inside the bed. In general, the NO concentration decreased monotonically along the freeboard and toward the exit flue; however, during combustion with high air staging and low to moderate excess air, a significant additional NO formation occurred near the secondary air injection point. The results show that the bed temperature increase does not affect the NO flue gas concentration significantly. There is a positive correlation between excess air and the NO flue gas concentration. The air staging operation is very effective in lowering the NO flue gas, but there is a limit for the first stage stoichiometry below which the NO flue gas starts rising again. This effect could be related with the coal rank

Environmental assessment of amending the Amager Bakke incineration plant in Copenhagen with carbon capture and storage

Amending municipal solid waste incineration with carbon capture and storage (CCS) is a new approach that can reduce the climate change impacts of waste incineration. This study provides a detailed analysis of the consequences of amending the new Amager Bakke incinerator in Copenhagen (capacity: 600,000 tonnes waste per year) with CCS as a post-combustion technology. Emphasis is on the changes in the energy flows and outputs as well as the environmental performance of the plant; the latter is assessed by life cycle assessment. Amending Amager Bakke with CCS of the chosen configuration reduces the electricity output by 50% due to steam use by the capture unit, but introducing post-capture flue gas condensation increases the heat output utilized in the Copenhagen district heating system by 20%. Thus, the overall net energy efficiency is not affected. The CCS amendment reduces the fossil CO(2) emissions to 40 kg CO(2) per tonne of incinerated waste and stores 530 kg biogenic CO(2) per tonne of incinerated waste. Potential developments in the composition of the residual waste incinerated or in the energy systems that Amager Bakke interacts with, do not question the benefits of the CCS amendment. In terms of climate change impacts, considering different waste composition and energy system scenarios, introducing CCS reduces in average the impact of Amager Bakke by 850 kg CO(2)-equivalents per tonne of incinerated waste. CCS increases the environmental impacts in other categories, but not in the same order of magnitude as the savings introduced within climate change

Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody.

A human monoclonal antibody, 41-7 [immunoglobulin G1(kappa)], directed against the transmembrane glycoprotein gp41 of the human immunodeficiency virus type 1 (HIV-1) has been produced by direct fusion of lymph node cells from an HIV-1-infected individual with a human B-lymphoblastoid cell line. The minimal essential epitope for 41-7 was mapped to a conserved seven-amino acid sequence, N-CSGKLIC-C, located within the N-terminal part of gp41. Antibodies blocking the binding of 41-7 could be detected in the serum of all HIV-1-infected individuals tested, irrespective of the stage of the infection. The epitope is located externally to the plasma membrane, and it is accessible to antibody in the native conformation of the glycoprotein. Despite this, no neutralizing activity of 41-7 could be demonstrated in vitro. These data indicate, directly and indirectly, that this immunodominant epitope on gp41, although exposed on the viral surface, elicits antibodies lacking antiviral activity and, hence, should be avoided in future vaccine candidates